The tweet was deleted by the author.
But we saved everything 🙂.
Definium Therapeutics announced it will report its third quarter 2026 financial results and recent business updates in the near future. The company said this follows a year marked by significant progress, including three positive topline Phase 3 readouts.
Further details on the financial results and business developments are expected to be shared during the upcoming report.
View post on X Loading...
Earlier this year, Definium Therapeutics provided updates on its Phase 3 studies of DT120 for major depressive disorder and anxiety at a leading neuropsychopharmacology event. Details of these clinical advancements were reported in a previous company announcement. The upcoming financial and business report will provide further information following these recent milestones.